ReviewOpen forum infectious diseases2018
Association Between Carbapenem Resistance and Mortality Among Adult, Hospitalized Patients With Serious Infections Due to
Review in Open forum infectious diseases, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 120 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
120 citing papers in PubMed, 3 syntheses or guidelines pooled it, 206 citations in OpenAlex.
- Pooled it
- Pooled it
- Burden of carbapenem non-susceptible infections in high-risk patients: systematic literature review and meta-analysis.Antimicrobial resistance and infection control · 2020Pooled it
- Real-World Applications of Imipenem-Cilastatin-Relebactam: Insights From a Multicenter Observational Cohort Study.Open forum infectious diseases · 2025Trial
- Comparison of Treatment Outcomes between Analysis Populations in the RESTORE-IMI 1 Phase 3 Trial of Imipenem-Cilastatin-Relebactam versus Colistin plus Imipenem-Cilastatin in Patients with Imipenem-Nonsusceptible Bacterial Infections.Antimicrobial agents and chemotherapy · 2020Trial
- Prospective validation and implementation of a model to identify patients with carbapenem-resistant Enterobacterales (CRE) carriage on admission to acute care hospitals.Infection control and hospital epidemiology · 2026Article
- Pre-Target Interception Defines Carbapenem Failure in Carbapenem-Resistant Enterobacterales: A Mechanistic Framework for Spatiotemporal Drug Reprogramming.Pharmaceutics · 2026Review
- Difficult-to-treat resistance (DTR), treatment, and outcomes of carbapenem-resistant Enterobacterales infections in the setting of IMP-type carbapenemase predominance in Japan.Microbiology spectrum · 2026Article
- Article
- ASP-COMPLEX: redefining antimicrobial stewardship to improve outcomes in high-risk patients with severe infections.Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia · 2026Review
- The pharmacokinetics/pharmacodynamics index of high-dose tigecycline in patients with carbapenem-resistant Enterobacterales bloodstream infection: a prospective study.BMC infectious diseases · 2026Article
- Epidemiology and clinical outcomes of carbapenamase-producing organism (CPO) colonization: a tertiary care center experience in Saudi Arabia.BMC infectious diseases · 2026Article
- Zinc-Driven Antibiotic Resistance Gene Dynamics During Vermicomposting: Insights into Co-Contamination Mitigation for Sustainable Manure Management.Antibiotics (Basel, Switzerland) · 2026Article
- Development and temporal validation of SCRAPS scoring tool to predict poor prognosis in gram negative sepsis patients requiring early intensive care or high dependency unit admission.BMC infectious diseases · 2026Observational
- Changes in Carbapenemase-Producing Carbapenem-Resistant Enterobacterales, 2019 to 2023.Annals of internal medicine · 2025Article
- Trends and relationship between antibiotic consumption and carbapenem-resistant Gram-negative bacteria at a tertiary hospital in shaanxi, China from 2011 to 2023.New microbes and new infections · 2025Article
- Cost-Effectiveness Analysis of Aztreonam-Avibactam (ATM-AVI) Versus Colistin + Meropenem (COL + MER) for the Treatment of Infections Caused by Metallo-β-Lactamase (MBL)-Producing Enterobacterales in Italy.PharmacoEconomics · 2025Article
- Paradoxical carbapenemase activity detected by modified carbapenemase inactivation (mCIM) method inJournal of clinical microbiology · 2025Article
- Surveillance and characterization of carbapenem-resistant Enterobacter cloacae complex from China, 2015-2018.BMC microbiology · 2025Article
- Epidemiology of carbapenem-resistant Enterobacterales infections in Tennessee, 2016-2022.Epidemiology and infection · 2025Article
60 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study quantified mortality associated with serious infections caused by carbapenem-resistant (CRE) and carbapenem-susceptible
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.